Frontline Treatment Selection in ROS1-Positive Advanced Non-Small Cell Lung Cancer: Choosing the Optimal Agent

The panel discusses first-line treatment selection once a ROS1 fusion is confirmed in a treatment-naive patient. All panelists favor lorlatinib as the preferred first-line agent based on duration of disease control exceeding historical comparators with median duration of response approaching 50 months, favorable tolerability, and superior CNS activity, which is particularly relevant given the high rate of brain metastases in this younger patient population.

A patient's experience is shared: within 4 days of starting lorlatinib at 600 mg, he reported feeling as well as before his diagnosis, describing resolution of fatigue, fevers, body aches, and abdominal pain, which are consistent with patient-reported outcome data from ASCO showing rapid symptomatic improvement, often within the first month of treatment. Earlier agents like crizotinib have ROS1 activity and can produce responses, but limited CNS penetration and shorter response durations represent meaningful limitations.

Dr. Rodriguez shares frustration with current NCCN guidelines listing all ROS1-active agents at the same category recommendation level without differentiation, acknowledging the absence of head-to-head data but advocating for clearer communication to community oncologists who must make frontline decisions today. The panel acknowledges guideline constraints while emphasizing that clinical experience and available efficacy and safety data can and should inform individualized recommendations.